Therapy for primary cardiac tumors: is there a role for heart transplantation?

A Gowdamarajan1, R E Michler

  • 1Department of Surgery, The Ohio State University School of Medicine, Columbus 43210, USA.

Insights

Orthotopic heart transplantation offers a potential cure for rare primary cardiac tumors. While successful for benign cases, its role in malignant tumors requires further investigation.

Area of Science:

  • Cardiology
  • Oncology
  • Transplantation Medicine

Background:

  • Primary cardiac tumors are rare, with benign types often surgically removable and malignant types rarely resectable.
  • Orthotopic heart transplantation (OHT) has been utilized for inoperable primary cardiac tumors.

Purpose of the Study:

  • To present the outcomes of 28 patients who underwent OHT for inoperable primary cardiac tumors.
  • To evaluate the efficacy of OHT for both benign and malignant cardiac neoplasms.

Main Methods:

  • Retrospective analysis of 28 patients who received OHT for primary cardiac tumors.
  • Categorization of tumors into benign (fibroma, rhabdomyoma, pheochromocytoma) and malignant (sarcoma, malignant fibrohistiocytoma, lymphoma) histologies.

Main Results:

  • Seven patients with benign tumors had a mean survival of 46 months.
  • Twenty-one patients with malignant tumors had a mean survival of 12 months.
  • Seven malignant cases survived a mean of 27 months without recurrence, suggesting potential benefit.

Conclusions:

  • OHT can provide a cure for benign primary cardiac tumors through complete resection.
  • The role of OHT for malignant cardiac tumors remains uncertain and requires further study.
  • Continued follow-up and research are necessary to define the optimal management strategies, including OHT, radiation, and chemotherapy.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...